Glaxosmithkline Intellectual Property Development Limited

Glaxo Group Limited

Glaxosmithkline LLC

Simon Peace

Graham George Adam Inglis

Mark Andrew Seefeld

Dennis Shinji Yamashita

Julie Nicole Hamblin

Andrew Sharpe

Kevin James Doyle

Vipulkumar Kantibhai Patel

Anthony William James Cooper

Niall Andrew Anderson

Nicholas Paul Barton

Armelle Le Gall

Ian B Campbell

Dirk Andries Heerding

Kenneth David Down

Sebastien Andre Campos

Gemma Victoria White

Edward Paul Cannons

Meagan B Rouse

John Martin Pritchard

Daniel Terence Tape

Heather Hobbs

Gianpaolo Bravi

Simon Nicolle

Kenneth C McNulty

Robert Charles Wheeler

Dennis S Yamashita

Ian Baxter Campbell

Kenneth C Mcnulty

Dirk A Heerding

The invention relates to compounds of formula (I): wherein R, R, R, R, L and A are as defined in the description and claims, or pharmaceutically acceptable salts thereof having mTOR kinase inhibitor activity. The invention also relates to pharmaceutical compositions including a compound of formula (I) or a pharmaceutically acceptable salt thereof, and to the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in therapy, including in the treatment of a disease or condition for which an mTOR kinase inhibitor activity is indicated, and in particular the treatment of idiopathic pulmonary fibrosis.

Chemical compounds

The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds of formula (I): and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular PI3-kinase activity.

The present invention relates to compounds of formula (I): or pharmaceutically acceptable salts or solvates thereof, processes for their preparation, pharmaceutical compositions containing these compounds, and their use in the treatment of allergic disorders, such as allergic rhinitis and asthma.

Bicyclic imidazole as DP1 receptor antagonists

Growing community of inventors

Stevenage, United Kingdom

Simon Peace